Could C-reactive protein and erythrocyte sedimentation rate support monitoring of dermatomyositis and polymyositis activity?

Página do item simplificado
dc.contributorSistema FMUSP-HC: Faculdade de Medicina da Universidade de São Paulo (FMUSP) e Hospital das Clínicas da FMUSP
dc.contributor.authorMIOSSI, Renata
dc.contributor.authorSOUZA, Fernando Henrique Carlos de
dc.contributor.authorSHINJO, Samuel Katsuyuki
dc.date.accessioned2017-08-01T15:16:01Z
dc.date.available2017-08-01T15:16:01Z
dc.date.issued2017
dc.description.abstractOBJECTIVES: To evaluate serum levels of C-reactive protein and erythrocyte sedimentation rates in patients with untreated newly diagnosed dermatomyositis or polymyositis and their correlation with clinical and laboratory parameters. METHODS: A cross-sectional study including 48 consecutive patients with untreated newly diagnosed dermatomyositis and polymyositis reviewed between 2002 and 2015 was conducted. Fifty healthy subjects were enrolled as controls. RESULTS: Patients with dermatomyositis and polymyositis had higher levels of C-reactive protein and erythrocyte sedimentation rate than healthy controls, but these values were not associated with clinical or laboratory parameters of disease activity either for dermatomyositis or for polymyositis. Additionally, erythrocyte sedimentation rate values correlated with pulmonary involvement as evidenced through computer tomography imaging (OR 1.15; 95%CI 1.01-1.31) only in patients with polymyositis. CONCLUSIONS: Although elevated, C-reactive protein and erythrocyte sedimentation rate are not sensitive parameters for measuring clinical and laboratory activity of dermatomyositis nor for polymiositis. However, erythrocyte sedimentation rate may be a valid parameter for screening pulmonary involvement, particularly in patients with polymyositis.
dc.description.abstractOBJETIVOS: Avaliar os níveis séricos da proteína C reativa (PCR) e da velocidade de hemossedimentação (VHS) em pacientes recém-diagnosticados com dermatomiosite (DM) e polimiosite (PM), sem tratamento prévio, correlacionando-os com parâmetros clínico-laboratoriais. MÉTODOS: Estudo transversal que incluiu 48 pacientes consecutivos com DM e PM (critérios de Bohan e Peter) recém-diagnosticados, sem tratamento medicamentoso, no período de 2002 a 2015. Foram incluídos 50 indivíduos saudáveis como grupo controle. RESULTADOS: Os pacientes apresentaram níveis mais elevados de VHS e PCR comparativamente aos controles saudáveis. Estes valores, porém, não se correlacionaram com os parâmetros clínicos e laboratoriais da atividade da doença (DM e PM). Somente em pacientes com PM a VHS apresentou relação com acometimento pulmonar na tomografia computadorizada [OR 1,15 (IC 95% 1,01-1,31)]. CONCLUSÕES: Apesar de aumentadas, a PCR e a VHS não são parâmetros sensíveis para a mensuração da atividade clínica e laboratorial de DM e PM., No entanto, a VHS pode ter validade no rastreio do acometimento pulmonar, particularmente em pacientes com PM.
dc.description.indexSciELO
dc.identifier.citationMEDICALEXPRESS, v.4, n.2, 2017
dc.identifier.doi10.5935/medicalexpress.2017.02.05
dc.identifier.issn2358-0429
dc.identifier.urihttps://observatorio.fm.usp.br/handle/OPI/21128
dc.language.isoeng
dc.publisherMavera Edições Técnicas e Científicas Ltda
dc.relation.ispartofMedicalExpress
dc.rightsopenAccess
dc.rights.holderCopyright Mavera Edições Técnicas e Científicas Ltda
dc.subjectDermatomyositis
dc.subjectpolymyositis
dc.subjectC-reactive protein
dc.subjecterythrocyte sedimentation rate
dc.subjectDermatomiosite
dc.subjectpolimiosite
dc.subjectproteína C reativa
dc.subjectvelocidade de hemossedimentação
dc.subject.wosHealth Care Sciences & Services
dc.titleCould C-reactive protein and erythrocyte sedimentation rate support monitoring of dermatomyositis and polymyositis activity?
dc.title.alternativeÉ POSSÍVEL SUPOR QUE A PROTEÍNA C REATIVA E A HEMOSSEDIMENTAÇÃO POSSAM SER USADAS PARA MONITORAR A ATIVIDADE DA DERMATOMIOSITE E DA POLIMIOSITE?
dc.typearticle
dc.type.categoryoriginal article
dc.type.versionpublishedVersion
dspace.entity.typePublication
hcfmusp.contributor.author-fmusphcRENATA MIOSSI
hcfmusp.contributor.author-fmusphcFERNANDO HENRIQUE CARLOS DE SOUZA
hcfmusp.contributor.author-fmusphcSAMUEL KATSUYUKI SHINJO
hcfmusp.description.issue2
hcfmusp.description.volume4
hcfmusp.origemsciELO
hcfmusp.origem.scieloSCIELO:S2358-04292017000200004
hcfmusp.relation.referenceAmerio P, 2002, EUR J DERMATOL, V12, P165
hcfmusp.relation.referenceBASSETSEGUIN N, 1990, ARCH DERMATOL, V126, P633, DOI 10.1001/archderm.126.5.633
hcfmusp.relation.referenceBohan A, 1975, N Engl J Med, V292, P344
hcfmusp.relation.referenceBriani C, 2006, AUTOIMMUNITY, V39, P161, DOI 10.1080/08916930600622132
hcfmusp.relation.referenceBrigden ML, 1999, AM FAM PHYSICIAN, V60, P1443
hcfmusp.relation.referenceBurnouf M, 2003, ANN DERMATOL VENER, V130, P313
hcfmusp.relation.referenceChen D, 2014, CLIN EXP RHEUMATOL, V32, P615
hcfmusp.relation.referenceDalakas MC, 2011, NEUROPATH APPL NEURO, V37, P226, DOI 10.1111/j.1365-2990.2010.01153.x
hcfmusp.relation.referenceDalakas MC, 2015, NEW ENGL J MED, V373, P393, DOI 10.1056/NEJMc1506827
hcfmusp.relation.referenceDalakas MC, 2015, NEW ENGL J MED, V372, P1734, DOI 10.1056/NEJMra1402225
hcfmusp.relation.referenceDi Rollo D, 2014, GIORN ITAL DERMAT V, V149, P525
hcfmusp.relation.referenceDiaz MTM, 2017, J Bras Patol Med Lab
hcfmusp.relation.referenceGABAY C, 1994, ARTHRITIS RHEUM, V37, P1744, DOI 10.1002/art.1780371206
hcfmusp.relation.referenceGo DJ, 2016, J KOREAN MED SCI, V31, P389, DOI [10.3346/jkms.2016.31.3.389, 10.3346/jkms.2016.31.3.339]
hcfmusp.relation.referenceIdeura G, 2007, RESP MED, V101, P1406, DOI 10.1016/j.rmed.2007.01.023
hcfmusp.relation.reference[林辉 Lin Hui], 2013, [四川大学学报. 医学版, Journal of Sichuan University. Medical Science Edition], V44, P805
hcfmusp.relation.referenceMALLYA RK, 1982, J RHEUMATOL, V9, P224
hcfmusp.relation.referenceMarie I, 2002, ARTHRIT RHEUM-ARTHR, V47, P614, DOI 10.1002/art.10794
hcfmusp.relation.referencePark JK, 2013, RHEUMATOLOGY, V52, P1336, DOI 10.1093/rheumatology/ket162
hcfmusp.relation.referenceCruellas Marcela Gran Pina, 2013, Clinics, V68, P909, DOI 10.6061/clinics/2013(07)04
hcfmusp.relation.referencePinhata MM, 2015, CLIN EXP RHEUMATOL, V33, P310
hcfmusp.relation.referenceRider LG, 2004, ARTHRITIS RHEUM, V50, P2281, DOI 10.1002/art.20349
hcfmusp.relation.referenceRider Lisa G., 2003, Journal of Rheumatology, V30, P603
hcfmusp.relation.referenceShinjo SK, 2015, CLIN EXP RHEUMATOL, V33, P336
hcfmusp.relation.referenceSouza Fernando Henrique Carlos de, 2011, Rev Bras Reumatol, V51, P428
hcfmusp.relation.referenceSouza FH, 2012, Rev Bras Reumatol, V52, P897
hcfmusp.relation.referenceSparsa A, 2002, ARCH DERMATOL, V138, P885, DOI 10.1001/archderm.138.7.885
hcfmusp.relation.referenceSun YC, 2013, RHEUMATOL INT, V33, P1295, DOI 10.1007/s00296-012-2545-7
hcfmusp.relation.referenceTanaka A, 2015, ARTHRITIS RES THER, V17, DOI 10.1186/s13075-015-0547-z
hcfmusp.relation.referenceYe S, 2007, CLIN RHEUMATOL, V26, P1647, DOI 10.1007/s10067-007-0562-9
relation.isAuthorOfPublication2833bf0a-6e3b-48a8-bfad-d3fdd3e20fa0
relation.isAuthorOfPublication4ba63a7c-235d-4b1a-a2ae-81b0d3e7880c
relation.isAuthorOfPublication07f179c5-58d8-4efe-832c-52095a9009d6
relation.isAuthorOfPublication.latestForDiscovery2833bf0a-6e3b-48a8-bfad-d3fdd3e20fa0
Arquivos
Pacote Original
Agora exibindo 1 - 1 de 1
Imagem de Miniatura
Nome:
art_MIOSSI_Could_Creactive_protein_and_erythrocyte_sedimentation_rate_support_2017.PDF
Tamanho:
285.87 KB
Formato:
Adobe Portable Document Format
Descrição:
publishedVersion (English)
Baixar
Coleções
Artigos e Materiais de Revistas Científicas - FM/MCM
Artigos e Materiais de Revistas Científicas - HC/ICHC
Artigos e Materiais de Revistas Científicas - LIM/17